PAION’s lead compound is Byfavo® (remimazolam), an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION is rolling out Byfavo® in selected European markets. Byfavo® is partnered in multiple territories outside of Europe. Byfavo® is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in the EU/EEA, Japan, the Philippines and South Korea for general anesthesia.
For more information on the safety of remimazolam, please refer to the EMA Summary of Product Characteristics (SmPC) and is accessible via https://www.ema.europa.eu/en/medicines/human/EPAR/byfavo.